Header

News archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

Showing 1807 results

May 2020

Media ReleaseMay 19, 2020
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with…
Media ReleaseMay 14, 2020
Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA…
StoryMay 12, 2020 Discovery
Moving from speculation to science during a pandemic
Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
Key ReleaseMay 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)…
StoryMay 06, 2020 Discovery
It takes an R&D village to fight a pandemic
Gervais Tougas shares his experience working on a Novartis task force dedicated to fighting the COVID-19 pandemic.
Media ReleaseMay 01, 2020
Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital…

April 2020